In addition, literature suggests that AS-IV has anti-inflammatory properties by inhibiting the phosphorylation of ERK1/2 and p38 in various diseases, such as atherosclerosis and hepatic steatosis (Gao et al., 2017; Del Rosario et al., 2020; Chen et al., 2021). This evidence concerns the gene MAPK3 and fatty liver disease.